Overview

Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function

Status:
Completed
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, parallel-group study in subjects with varying degrees of renal function to assess the safety, tolerability, and Pharmacokinetics of a single 10 mg oral dose of CIN-107.
Phase:
Phase 1
Details
Lead Sponsor:
CinCor Pharma, Inc.